SOUTH JORDAN, Utah—Daniel LeSueur, Chief Operating Officer of Health Catalyst , Inc. (NASDAQ:HCAT), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, LeSueur sold 5,209 shares of common stock on November 5, at an average price of $7.7034 per share, amounting to a total transaction value of $40,127.
This transaction was executed as part of a pre-established trading plan adopted by LeSueur on March 7, 2024, in accordance with Rule 10b5-1. Following this sale, LeSueur retains ownership of 129,690 shares in the company.
In other recent news, Health Catalyst, a leader in healthcare data and analytics, reported its Q3 2024 financial results. The company's leadership, including CEO Dan Burton, CFO Jason Alger, and COO Dan LeSueur, provided a positive outlook on the company's growth trajectory and financial expectations for the remainder of 2024 and 2025. The earnings conference call did not highlight any specific financial misses or underperformance, indicating a strong performance in the third quarter. The company's financial results and future projections were presented in accordance with the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Despite no specific details on the Q&A session, the company's confidence in future growth was evident, suggesting potential for strong performance in upcoming periods. These are recent developments in the company's financial landscape, providing valuable insights for investors and stakeholders. The detailed financial results are accessible through the press release and the Form 8-K available on the Investor Relations section of the Health Catalyst website.
InvestingPro Insights
While Daniel LeSueur's recent stock sale might raise eyebrows, it's important to consider the broader context of Health Catalyst's financial performance and market position. According to InvestingPro data, Health Catalyst has shown strong momentum recently, with a significant 61.68% price return over the last three months and a 30.68% return over the past six months. This upward trend suggests that the market is increasingly optimistic about the company's prospects.
Despite not being profitable over the last twelve months, InvestingPro Tips indicate that analysts expect Health Catalyst to become profitable this year. This positive outlook is further supported by the expectation of net income growth in the current year. These projections could explain why the stock has been performing well despite the insider sale.
It's worth noting that Health Catalyst operates with a moderate level of debt, which provides some financial flexibility. The company's price-to-book ratio of 1.41 as of the last twelve months ending Q3 2024 suggests that the stock might be reasonably valued relative to its book value.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Health Catalyst, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.